AvalehtJNJB34 • BVMF
add
Johnson & Johnson BDR
Viimane sulgemishind
62,18 R$
Tänane vahemik
61,50 R$ - 63,33 R$
Aasta vahemik
49,19 R$ - 63,86 R$
Turuväärtus
374,14 mld USD
Keskmine maht
12,81 tuh
Uudised
JNJ
0,25%
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Käive | 22,47 mld | 5,25% |
Põhitegevusega seonduv kulu | 10,20 mld | 18,80% |
Puhastulu | 2,69 mld | −89,65% |
Puhaskasumimarginaal | 11,99 | −90,16% |
Puhaskasum aktsia kohta | 2,42 | −9,02% |
EBITDA | 7,36 mld | −10,41% |
Tõhus maksumäär | 19,29% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 20,30 mld | −13,67% |
Kogu vara | 178,29 mld | 7,36% |
Kõik kohustused | 108,13 mld | 14,02% |
Kogu omakapital | 70,16 mld | — |
Emiteeritud aktsiate arv | 2,41 mld | — |
Hinna ja väärtuse suhe P/B | 2,13 | — |
Varade tasuvus | 7,66% | — |
Kapitali tasuvus | 12,58% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Puhastulu | 2,69 mld | −89,65% |
Põhitegevuse rahakäive | 7,99 mld | — |
Investeeringute raha | −3,13 mld | — |
Finantseerimise raha | −9,88 mld | — |
Raha ja raha ekvivalentide muutus | −4,90 mld | — |
Tasuta rahavoog | 5,50 mld | — |
Teave
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 40 on the 2023 Fortune 500 list of the largest United States corporations. In 2023, the company was ranked 40th in the Forbes Global 2000. Johnson & Johnson has a global workforce of approximately 130,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato.
Johnson & Johnson was founded in 1886 by three brothers, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, selling ready-to-use sterile surgical dressings. In 2023, the company split-off its consumer healthcare business sector into a new publicly traded company, Kenvue. The company is exclusively focused on developing and producing pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA. Wikipedia
Tegevjuht
Asutatud
jaan 1886
Veebisait
Töötajate arv
131 900